ERBB2 and gastric cancer: To this end we chose to examine the efficacy of the A5/F4 oligoclonal alone and in combination with trastuzumab using the NCI-N87 ERBB2+ gastric cancer xenograft model, as inhibiting ERBB3 in the setting of ERBB2+ gastric cancer represents a promising approach for the treatment of this disease.